Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 46
Lancet Reg Health Eur ; 25: 100567, 2023 Feb.
Article in English | MEDLINE | ID: covidwho-2242315
Ir J Med Sci ; 2023 Feb 09.
Article in English | MEDLINE | ID: covidwho-2232083


We summarized through systematic review and meta-analysis of observational studies the risk of mortality as well as severe illness of COVID-19 caused by omicron variant relative to delta variant of SARS-CoV-2. A total of twelve studies were included. Our results showed significantly reduced odds of mortality (pooled OR = 0.33; 95% CI: 0.16-0.67) and significantly reduced odds of severe illness (pooled OR = 0.24; 95% CI: 0.21-0.28) in patients infected with the omicron variant of SARS-CoV-2 relative to their counterparts infected with the delta variant. Findings of lower disease severity following infection with the omicron variant of SARS-CoV-2 than the delta variant are encouraging during the ongoing transition from the pandemic phase into the endemic phase of COVID-19.

Hosp Pharm ; 56(6): 629-632, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-2153273
J Gen Intern Med ; 2022 Nov 22.
Article in English | MEDLINE | ID: covidwho-2129105
[Unspecified Source]; 2020.
Non-conventional in English | [Unspecified Source] | ID: grc-750593
Endocr Res ; 46(2): 51-52, 2021.
Article in English | MEDLINE | ID: covidwho-1104646


Previous study reported that preadmission insulin treatment in patients with coronavirus disease 2019 (COVID-19) and concurrent diabetes was associated with a significantly increased odds of mortality. However, such association may be modified by possible baseline differences in glycemic control between insulin users and non-insulin users. Misinterpretation of the association between insulin treatment and mortality could lead to confusion in clinical practice and hospitalized patients with COVID-19 for whom insulin treatment is appropriately indicated may be omitted from such treatment. However, requirement for insulin during hospitalization for COVID-19 may be a marker of poor prognosis and as such could be used to identify patient population who require more aggressive treatments to prevent mortality.

COVID-19 , Diabetes Mellitus , Hospitalization , Humans , Insulin , SARS-CoV-2
Eur J Prev Cardiol ; 28(18): e52, 2022 02 09.
Article in English | MEDLINE | ID: covidwho-1099596
Acta Diabetol ; 58(2): 245-246, 2021 02.
Article in English | MEDLINE | ID: covidwho-1086597
Card Fail Rev ; 6: e32, 2020 Mar.
Article in English | MEDLINE | ID: covidwho-1069999